Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 2025 Apr 25.

Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals. 2023;16(6):836.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853–76.

PubMed  PubMed Central  CAS  Google Scholar 

Yaribeygi H, Farrokhi FR, Abdalla MA, et al. The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes. J Diabetes Res. 2021;2021:1–10.

Article  Google Scholar 

Lecis D, Prandi FR, Barone L, et al. Beyond the cardiovascular effects of glucagon-like peptide-1 receptor agonists: body slimming and plaque stabilization. Are new statins born? Biomolecules. 2023;13(12):1695.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kajikawa M, Higashi Y. Obesity and endothelial function. Biomedicines. 2022;10(7):1745.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tang ST, Tang HQ, Su H, et al. Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation. Biomed Pharmacother. 2019;113:108667.

Article  PubMed  CAS  Google Scholar 

Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;22(13):142.

Article  Google Scholar 

Wu Q, Li D, Huang C, et al. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomed Pharmacother. 2022;153:113517.

Article  PubMed  CAS  Google Scholar 

Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S. Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review. Front Cardiovasc Med. 2024;11:1446468.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dai Y, Dai D, Wang X, Ding Z, Li C, Mehta JL. GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A. J Cardiovasc Pharmacol. 2014;64(1):47–52.

Article  PubMed  CAS  Google Scholar 

Katare R, Riu F, Rowlinson J, et al. Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscler Thromb Vasc Biol. 2013;33(8):1872–80.

Article  PubMed  CAS  Google Scholar 

Zhang Y, Wang S, Zhou Q, et al. Novel angiogenesis role of GLP-1(32–36) to rescue diabetic ischemic lower limbs via GLP-1R-dependent glycolysis in mice. ATVB. 2024;44(6):1225–45.

Article  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Article  PubMed  CAS  Google Scholar 

Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

Article  PubMed  CAS  Google Scholar 

Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907.

Article  PubMed  CAS  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.

Article  PubMed  CAS  Google Scholar 

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.

Article  PubMed  CAS  Google Scholar 

McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001–12.

Article  PubMed  CAS  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.

Article  PubMed  CAS  Google Scholar 

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

Article  PubMed  CAS  Google Scholar 

Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. ATVB. 2013;33(9):2252–60.

Article  CAS  Google Scholar 

Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med. 2013;18(4):176–84.

Article  PubMed  PubMed Central  Google Scholar 

Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405:1580–93.

Article  PubMed  CAS  Google Scholar 

Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lepore JJ, Olson E, Demopoulos L, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail. 2016;4(7):559–66.

Article  PubMed  Google Scholar 

Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE )—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77.

Article  PubMed  CAS  Google Scholar 

Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care. 2016;39(2):e22–3.

Article  PubMed  CAS  Google Scholar 

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817–21.

Article  PubMed  Google Scholar 

Zhao H, Liu Y, Liu M, et al. Clinical outcomes with GLP-1 receptor agonists in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2023;83(14):1293–307.